Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results.
Earnings per share rose 10.96% over the past year to ($0.65), which beat the estimate of ($0.80).
Revenue of $15,878,000 rose by 1366.11% year over year, which missed the estimate of $16,500,000.
Earnings guidance hasn't been issued by the company for now.
Intra-Cellular Therapies hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 10, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/c6x5yerd
Company's 52-week high was at $40.01
52-week low: $16.90
Price action over last quarter: down 1.13%
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.